CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 83 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q2 2018. The put-call ratio across all filers is 1.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $38,000 | +18.8% | 6,930 | +5.0% | 0.00% | – |
| Q3 2019 | $32,000 | -33.3% | 6,600 | -3.6% | 0.00% | – |
| Q2 2019 | $48,000 | +4.3% | 6,850 | +3.0% | 0.00% | – |
| Q1 2019 | $46,000 | +24.3% | 6,650 | +3.1% | 0.00% | – |
| Q4 2018 | $37,000 | -27.5% | 6,450 | -3.7% | 0.00% | -100.0% |
| Q3 2018 | $51,000 | +59.4% | 6,700 | +9.0% | 0.00% | – |
| Q2 2018 | $32,000 | -25.6% | 6,145 | -14.6% | 0.00% | -100.0% |
| Q1 2018 | $43,000 | +30.3% | 7,195 | +53.2% | 0.00% | – |
| Q4 2017 | $33,000 | +17.9% | 4,695 | +18.9% | 0.00% | – |
| Q3 2017 | $28,000 | +7.7% | 3,950 | -4.8% | 0.00% | – |
| Q2 2017 | $26,000 | -25.7% | 4,150 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $35,000 | +40.0% | 4,150 | +38.3% | 0.00% | 0.0% |
| Q4 2016 | $25,000 | +25.0% | 3,000 | 0.0% | 0.00% | – |
| Q3 2016 | $20,000 | +300.0% | 3,000 | +50.0% | 0.00% | – |
| Q2 2016 | $5,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $27,550,000 | 20.34% |
| AdvisorShares Investments LLC | 380,750 | $2,079,000 | 1.29% |
| ETF MANAGERS GROUP, LLC | 5,779,642 | $31,557,000 | 1.10% |
| DAFNA Capital Management LLC | 297,300 | $1,623,000 | 0.56% |
| GENERAL AMERICAN INVESTORS CO INC | 632,400 | $3,453,000 | 0.32% |
| Aries Wealth Management | 27,900 | $160,000 | 0.10% |
| Virtus ETF Advisers LLC | 81,751 | $446,000 | 0.07% |
| Omnia Family Wealth, LLC | 21,726 | $119,000 | 0.06% |
| HighVista Strategies LLC | 12,200 | $67,000 | 0.05% |
| WOODSTOCK CORP | 57,213 | $312,000 | 0.05% |